Silence Therapeutics plc reported financial results for the second quarter ended June 30, 2026. The company posted a net loss of $12.3 million, or $0.09 per share, compared to a net loss of $27.4 million in the prior year period. Research and development expenses decreased to $9.1 million from $17.6 million, primarily due to completed Phase 3 readiness for zerlasiran and reduced personnel costs. Cash and cash equivalents stood at $72.1 million as of June 30, 2026. Business highlights include the completion of patient dosing in the Phase 2 SANRECO trial for divesiran in polycythemia vera and positive preclinical data for SLN365 and SLN098. Silence Therapeutics is a global clinical-stage biotechnology company developing siRNA therapies.
